NIH Reporter #5P01CA217959-08

NCI Solicits Research on Tumor Microenvironment-Dependent Therapy Resistance in Neuroblastoma

This opportunity is issued by the National Cancer Institute (NCI), part of the National Institutes of Health (NIH), seeking research proposals on therapy resistance in neuroblastoma: - Government Buyer: - National Cancer Institute (NCI), NIH - Research Focus: - Investigate mechanisms of therapy resistance in neuroblastoma - Emphasis on tumor microenvironment components, including tumor-associated macrophages (TAM) and cancer-associated fibroblasts (CAF) - Preclinical testing of inhibitors and cellular therapies - Translational research with potential for clinical trial application - Project Details: - Conducted by the Children's Hospital of Philadelphia - Associated with FOA PAR-20-077 - Budget of $359,100 for the specified fiscal year - Notable Requirements: - No specific OEMs, vendors, products, or part numbers mentioned - No unique license or classification requirements indicated

Description

This project focuses on understanding mechanisms of therapy resistance in neuroblastoma, particularly involving tumor microenvironment components such as tumor-associated macrophages (TAM) and cancer-associated fibroblasts (CAF). It involves preclinical testing of inhibitors and cellular therapies. The project is funded by the National Cancer Institute (NCI) under the NIH with a budget of $359,100 for fiscal year 2026. The project duration spans from September 18, 2017, to February 28, 2029, and is associated with the FOA PAR-20-077. The research is conducted by the Children's Hospital of Philadelphia and emphasizes translational research with potential clinical trial implications.

View original listing